Think about how involved you want to be. Some patients are very involved in their healthcare from the start, while others might prefer not to ask too many questions or talk too much about their diagnosis or treatment. If you tend to be less involved, consider that taking an active role in getting an accurate diagnosis and making treatment decisions could have a positive effect on your health and quality of life. You can enlist the help of family members, friends, other cancer patients, and patient advocates to support you with provider communications. Remember that you and members of your oncology team are working together to beat blood cancer.
Ask questions. But don’t just ask questions – make sure you take notes in case you forget anything that you might want to remember later. Not sure what to ask? Go to www.lls.org/whattoask to download printable question guides you can take with you on your medical appointments.
Find out what lines of communication are available to you. Are you the type of person that picks up the phone when you have a question or are you more likely to want to send an email? Ask your medical team if they wouldn’t mind you calling or emailing them with additional questions.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...